FatDAO

FatDAO

Metabolic Health

FatDAO addresses the global obesity crisis, aiming to advance research and solutions for weight management and metabolic health. With 2.2 billion overweight or obese adults worldwide, obesity and related diseases like diabetes and cardiovascular conditions severely impact public health and quality of life. Our vision is to become the “on-chain Eli Lilly,” driving breakthroughs in obesity treatment and reshaping the future of metabolic health.

Learn more:

Market Hypothesis

20 Billion

Affected People

$4T

Economic Impact

$150B

Market Cap

Overweight and obesity pose a severe threat, contributing to numerous health complications and placing a significant strain on the healthcare system.



Traditional weight-loss methods, like diet, exercise, medications, and surgery, can have different levels of success. The most prominent treatment today is semaglutide (Ozempic), a GLP-1 agonist, which has demonstrated significant efficacy. However, ...

Research Focus Areas
Weight Management Solutions

Weight Management Solutions

Our research explores innovative probiotic strategies for obesity treatment, targeting safer, more cost-effective metabolic interventions. By isolating and validating novel synbiotic combinations, we aim to naturally modulate metabolism and reduce fat accumulation, presenting a promising alternative to traditional pharmacological approaches.


Healthy Aging

Healthy Aging

Obesity and metabolic dysfunction accelerate aging processes by disrupting adipose tissue's endocrine function. Our research explores how interventions like targeted probiotics and metabolic modulators can mitigate age-related decline, improve insulin sensitivity, reduce inflammation, and promote healthier longevity.


Metabolic and Mental Well-being

Metabolic and Mental Well-being

The gut-brain communication critically influences appetite, mood, and cognition. Metabolic disorders like obesity frequently co-occur with mental health conditions. Fat DAO will fund research exploring how the gut microbiome impacts the gut-brain axis.


Team & Community
Jake Lee

Jake Lee

Ph.D.

PhD in Gastroenterology, is a distinguished scientist and visionary co-founder leading our research efforts. With over eight years...

Collins He

Collins He

PhD (Molecular Nutrition & Metabolomics), University of Tokyo Postdoctoral Research Fellow (Gut Microbiome & Therapeutic Interventions)

Combines deep pharmaceutical R&D expertise from Takeda with entrepreneurial success in health & wellness. Previously worked at AMED...

Alan Kim

Alan Kim

MA

Alan, MA in Communication from Seoul National University, used to work in Bayer China's marketing department, and also...

@FatDAO_ on 𝕏

Discord community

Telegram community

Project Roadmap
Q2-Q3 2025
FatLab establishment & launch initial probiotic pipeline
Q4 2025
Secure IP for initial product via IP-NFT & develop new probiotic food formulas
Q1-Q2 2026
R&D on multiple probiotics pipelines
Q3-Q4 2026
Achieve Key Pre-clinical Milestones & File Initial Regulatory Submissions
2027
Conduct pilot clinical studies
2028
Scale-up manufactory and commercialization
Value Capture Model

FatDAO champions sustainable innovation through our ""Research-Revenue-Research Flywheel.""...

Value Capture Model Diagram
Recommended Reads
Beneficial Effects of Anti-Inflammatory Diet in Modulating Gut Microbiota and Controlling Obesity

NHI

Beneficial Effects of Anti-Inflammatory Diet in Modulating Gut Microbiota and Controlling Obesity


Prebiotics, probiotics, synbiotics and postbiotics to adolescents in metabolic syndrome

Clinical Nutrition

Prebiotics, probiotics, synbiotics and postbiotics to adolescents in metabolic syndrome


Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics

NIH

Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics